- File Under HCV News
Researchers evaluated adherence to treatment in a cohort of 401 patients with chronic HCV genotype 1. All participants had been enrolled in the Virahep-C study and received therapy with pegylated interferon (PEG) and ribavirin (RBV) for 24 weeks, with responders receiving an additional 24 weeks (n=242). Adherence was measured using the Medication Event Monitoring System, which recorded when the medication container was opened via a computer chip in the cap.
Full Story »